In bladder and prostate cancers, treatment with chemotherapeutic agents such as gemcitabine or paclitaxel induces the release of HMGB1, which subsequently enhances autophagic activity via direct interaction with Beclin-1. The gene discussed is HMGB1; the disease is prostate carcinoma.